Latest News

Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn

Drug manufacturer Perrigo has completed the sale of its right to the royalty stream from the global net sales of the drug Tysabri (natalizumab) to Royalty Pharma's (RPI) affiliate RPI Finance...

Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn

RGC, UK Biobank and GSK launch new initiative to improve disease diagnosis

Regeneron Genetics Center (RGC), UK Biobank and GSK have launched a gene sequencing initiative on the world's detailed health...

RGC, UK Biobank and GSK launch new initiative to improve disease diagnosis

Pierre Fabre and H-Immune to develop new cancer immunotherapies

French pharmaceutical company Pierre Fabre and H-Immune have entered a strategic research partnership to develop new cancer...

Pierre Fabre and H-Immune to develop new cancer immunotherapies

Emergent signs $100m BARDA contract to deliver BioThrax

Emergent signs $100m BARDA contract to deliver BioThrax

PCC acquires Intrathecal Therapy business from Mallinckrodt for $203m

PCC acquires Intrathecal Therapy business from Mallinckrodt for $203m

Bellus Health agrees to sell Thallion to US firm Taro Pharmaceuticals

Bellus Health has signed an agreement to sell its wholly owned subsidiary Thallion Pharmaceuticals, including all the rights to the Shigamab drug candidate to US-based Taro...

Bellus Health agrees to sell Thallion to US firm Taro Pharmaceuticals

UK NICE Board approves changes to drug evaluation process

UK NICE Board approves changes to drug evaluation process

GSK submits application to FDA for expanded indication of influenza vaccine

GSK submits application to FDA for expanded indication of influenza vaccine

FDA grants IND clearance for Servier’s UCART19 to treat relapsed / refractory ALL

The US Food and Drug Administration (FDA) has granted an investigational new drug (IND) clearance to Servier to proceed with the clinical development of UCART19 in the...

FDA grants IND clearance for Servier’s UCART19 to treat relapsed / refractory ALL

FDA grants orphan drug designation to Boehringer Ingelheim’s antibody BI 836858

The US Food and Drug Administration (FDA) has granted orphan drug designation to Boehringer Ingelheim’s anti-CD33 monoclonal antibody, BI 836858, which is being investigated in the treatment...

FDA grants orphan drug designation to Boehringer Ingelheim’s antibody BI 836858

Pharnext and Galapagos partner to generate new pipeline of synergistic drug combinations

French biopharmaceutical company Pharnext has announced a research and development (R&D) agreement with Galapagos to generate a new pipeline of synergistic drug...

Pharnext and Galapagos partner to generate new pipeline of synergistic drug combinations

BerGenBio and Merck to evaluate BGB324 with Keytruda in NSCLC and breast cancer

Norwegian-based biopharmaceutical company BerGenBio has signed an agreement to clinically evaluate its lead candidate BGB324 with Merck’s Keytruda (pembrolizumab) in patients with...

BerGenBio and Merck to evaluate BGB324 with Keytruda in NSCLC and breast cancer

Trump's tweet causes pharmaceutical company shares to plunge

US President Donald Trump has pledged to introduce a new system that will help decrease the pricing of drugs and increase competition in the pharmaceutical...

Trump's tweet causes pharmaceutical company shares to plunge

Ferring Pharmaceuticals acquires Apricus’ ex-US Vitaros assets and rights

Ferring Pharmaceuticals acquires Apricus’ ex-US Vitaros assets and rights

French biotech MedDay acquires Profilomic's health division to enhance research capabilities

French biotechnology company MedDay has acquired the health division of Profilomic to bolster its current metabolomics research platform...

French biotech MedDay acquires Profilomic's health division to enhance research capabilities

EC grants marketing authorisation for Actelion’s Ledaga to treat MF-CTCL

The European Commission (EC) has granted marketing authorisation for 160mcg of Actelion’s Ledaga (chlormethine gel) to treat mycosis fungoides-type cutaneous T-cell lymphoma...

EC grants marketing authorisation for Actelion’s Ledaga to treat MF-CTCL

Scotland’s NPSC and MRC sign MoU to accelerate drug discovery

Scotland’s NPSC and MRC sign MoU to accelerate drug discovery

Vertex to acquire Concert Pharmaceuticals’ cystic fibrosis drug for $250m

US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert...

Vertex to acquire Concert Pharmaceuticals’ cystic fibrosis drug for $250m

Vernalis and Servier sign oncology drug discovery collaboration

UK-based Vernalis and French pharmaceutical company Servier have entered a new oncology drug discovery...

Vernalis and Servier sign oncology drug discovery collaboration

FDA approves Serenity’s Noctiva nasal spray for frequent night-time urination

The US Food and Drug Administration (FDA) has approved Noctiva (desmopressin acetate) nasal spray treatment for adults who wake up at least two times every night due to overproduction of urine,...

FDA approves Serenity’s Noctiva nasal spray for frequent night-time urination

NICE approves Intercept’s Ocaliva for use by UK's NHS

The National Institute for Health and Care Excellence (NICE) in the UK has approved Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for routine use by the National Health Service (NHS)...

NICE approves Intercept’s Ocaliva for use by UK's NHS
cachename:Newscachekey:rd-137342983_-779801984_rd-1665407042_1857678299_rd-488908060_1460672566_ap1460672566_1857678299_541212976